Sanifit raises $41M for late-stage R&D program

Forbion has joined a syndicate backing a $41 million round for Spain's Sanifit, which is plotting a Phase IIb study of its lead drug SNF472, which is designed to treat cardiovascular disease related to calcification in patients with end-stage renal disease. That should be enough money to get the company through late stage development for calciphylaxis. The biotech also announced that it had named longtime GSK vet Russell Greig as chairman of the board. The round was led by Ysios Capital and included Lundbeckfond Ventures, Gilde Healthcare, Edmond de Rothschild Investment Partners, "la Caixa" and Baxter Healthcare. Release

Suggested Articles

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.

Operation Warp Speed is living up to its name as AstraZeneca is teaming up with IQVIA to boost its R&D for its pandemic shot.

The deal, which is worth up to $160 million per molecule in milestones, comes as Junshi tries to pull off a $684 million IPO.